Biotech's smart money is focused on disease prevention, boosting immune systems and longevity

NickOttens · June 30, 2020, 5:47pm

Story by Dmitry Kaminskiy and Kate Batz in MarketWatch

The COVID-19 pandemic will change the global business landscape to its core. Investors are switching their attention from what was previously considered important — sectors such as real estate, tourism and hospitality — to what is truly important: human health.

The pandemic clearly will provide a tremendous boost to the biotech and bio-medicine industries, with a particular emphasis on preventive medicine. Recently, for example, two venture-funded rounds of more than $1 billion each (Arch Venture Partners and Qiming Venture Partners) were finalized. Meanwhile, several biotech companies closed sizeable funding rounds (e.g., Mabwell biotech’s recent $278.5 million Series A injection, iTeos Therapeutics’ recent $125 million Series B2 financing, Affinivax’s recent $120 million Series B round, among others).

Click here to read the rest.